The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shedko E.D.

Central Research Institute of Epidemiology, Moscow, Russia

Tyumentseva M.A.

Central Research Institute of Epidemiology, Moscow, Russia

Cerebrospinal fluid molecular biomarkers of multiple sclerosis

Authors:

Shedko E.D., Tyumentseva M.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7): 95‑102

DOI: 10.17116/jnevro201911907195

Read: 1592 times

Download PDF (RU)
Contact the author
Table of contents

CEREBROSPINAL FLUID MOLECULAR BIOMARKERS OF MULTIPLE SCLEROSIS
CEREBROSPINAL FLUID MOLECULAR BIOMARKERS OF MULTIPLE SCLEROSIS

To cite this article:

Shedko ED, Tyumentseva MA. Cerebrospinal fluid molecular biomarkers of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):95‑102. (In Russ.)
https://doi.org/10.17116/jnevro201911907195

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Masks of autoimmune diseases: a multidisciplinary approach to the problem. Journal of Respiratory Medi­cine. 2025;(1):58-64
Diagnoctic test accu­racy of nucleated red blood cells in non-hematologic inte­nsive care patients (meta-analysis). Russian Journal of Anesthesiology and Reanimatology. 2025;(2):68-82
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Diagnostic and prognostic pote­ntial of modern biomarkers in community-acquired pneumonia in children. Russian Journal of Preventive Medi­cine. 2025;(4):130-135
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130
Abstract:

Multiple sclerosis (MS) is a chronic autoimmune disease affecting brain and spinal cord. Nowadays, MS diagnosis at early stages is difficult since the causes and mechanisms of the disease onset have not yet been fully discovered. The MS diagnosis is a complex process, and understanding molecular mechanisms of the disease as well as searching for biomarkers are principal directions in MS diagnosis. In this review, the authors present promising biomarkers for MS found in the cerebrospinal fluid.

Keywords:

autoimmune diseases
multiple sclerosis
biomarkers
cerebrospinal fluid

Authors:

Shedko E.D.

Central Research Institute of Epidemiology, Moscow, Russia

Tyumentseva M.A.

Central Research Institute of Epidemiology, Moscow, Russia

Close metadata

References:

  1. Goldenberg MM. Multiple Sclerosis Review. Pharmacy and Therapeutics. 2012;37(3):175-184.
  2. Loma I, Heyman R. Multiple Sclerosis: Pathogenesis and Treatment. Current Neuropharmacology. 2011;9(3):409-416. https://doi.org/10.2174/157015911796557911
  3. Katdare A, Ursekar M. Systematic imaging review: Multiple Sclerosis. Annals of Indian Academy of Neurology. 2015;18(suppl 1):24-29. https://doi.org/10.4103/0972-2327.164821
  4. Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am. 2009;19(1):45-58. https://doi.org/10.1016/j.nic.2008.08.002
  5. Gourraud PA, McElroy JP, Caillier SJ, Johnson BA, Santaniello A, Hauser SL, Oksenberg JR. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol. 2011;69(1):65-74. https://doi.org/10.1002/ana.22323
  6. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L. An altered immune response to Epstein—Barr virus in multiple sclerosis: A prospective study. Neurology. 2004;62:2277-2282. https://doi.org/10.1212/01.WNL.0000130496.51156.D7
  7. Nielsen JM, Korteweg T, Barkhof F, Uitdehaag BM, Polman CH. Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol. 2005;58:781-783. https://doi.org/10.1002/ana.20632
  8. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis. Part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4:281-288. https://doi.org/10.1016/S1474-4422(05)70071-5
  9. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-218. Review. https://doi.org/10.1111/j.1750-3639.2007.00064.x
  10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
  11. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold C, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2
  12. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84(8):909-914. https://doi.org/10.1136/jnnp-2012-304695
  13. Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol. 2013;262(1-2):1-10. https://doi.org/10.1016/j.jneuroim.2013.06.014
  14. Nakashima I, Fujihara K, Sato S, Itoyama Y. Ologoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol. 2005;159:133-136. https://doi.org/10.1016/j.jneuroim.2004.09.011
  15. Fortini AS, Sanders EL, Weinshenker BG, Katzmann JA. Cerebrospinal fluid oligoclonal band in the diagnosis of multiple clerosis. Am J Clin Pathol. 2003;120:672-675. https://doi.org/10.1309/EM7K-CQR4-GLMH-RCX4
  16. Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180:17-28. https://doi.org/10.1016/j.jneuroim.2006.07.006
  17. Tomioka R, Matsui M. Biomarkers for multiple sclerosis. Internal medicine. 2014;53:361-365. https://doi.org/10.2169/internalmedicine.53.1246
  18. Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler. 2008;14(9):1208-1213. https://doi.org/10.1177/1352458508095729
  19. Villar LM, Sádaba MC, Roldán E, Masjuan J, González-Porqué P, Villarrubia N, Espiño M, García-Trujillo JA, Bootello A, Alvarez-Cermeño JC. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. Journal of Clinical Investigation. 2005;115(1):187-194. https://doi.org/10.1172/JCI200522833
  20. Alvarez-Cermeno JC, Munoz-Negrete FJ, Costa-Frossard L, de la Maza SS, Villar LM, Rebolleda G. Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. J Neurol Sci. 2016;360:41-44. https://doi.org/10.1016/j.jns.2015.11.030
  21. Villar LM, Picón C, Costa-Frossard L, Alenda R, García-Caldentey J, Espiño M, Muriel A, Álvarez-Cermeño JC. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015;22(8):1169-1175. https://doi.org/10.1111/ene.12579
  22. Sádaba MC, Tzartos J, Paíno C, García-Villanueva M, Alvarez-Cermeño JC, Villar LM, Esiri MM. Axonal and oligodendrocytelocalized IgM and IgG deposits in MS lesions. J Neuroimmunol. 2012;247(1-2):86-94. https://10.1016/j.jneuroim.2012.03.020
  23. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138(Pt 4):918-931. https://doi.org/10.1093/brain/awv017
  24. Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. Journal of Epithelial Biology & Pharmacology. 2012;5:1-9.
  25. Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler. 2015;21(10):1251-1261. https://doi.org/10.1177/1352458514561906
  26. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479-501. https://doi.org/10.1146/annurev-physiol-012110-142250
  27. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34. https://doi.org/10.1186/1742-2094-7-34
  28. Martínez MA, Olsson B, Bau L, Matas E, Cobo Calvo Á, Andreasson U, Blennow K, Romero-Pinel L, Martínez-Yélamos S, Zetterberg H. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550-561. https://doi.org/10.1177/1352458514549397
  29. Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, Frederiksen JL. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590-598. https://doi.org/10.1177/1352458515599074
  30. Borràs E, Cantó E, Choi M, Villar ML, Álvarez-Cermeño JC, Chiva C, Montalban X, Vitek O, Comabella M, Sabidó E. Protein-based classifier to predict conversion from clinically isolated syndrome to multiple sclerosis. Mol Cell Proteomics. 2016;15(1):318-328. https://doi.org/10.1074/mcp.M115.053256
  31. Mollgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. Eur J Neurol. 2016;23(5):898-905. https://doi.org/10.1111/ene.12960
  32. Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206-1213. https://doi.org/10.1212/WNL.0b013e31821432ff
  33. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322-1329. https://doi.org/10.1212/WNL.0b013e3181a0fe3f
  34. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287-292. https://doi.org/10.1177/1352458509359725
  35. Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085-1093. https://doi.org/10.1093/brain/awy021
  36. Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. 2018;24(10):1301-1307. https://doi.org/10.1177/1352458518782005
  37. Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatric disease and treatment. 2018;14:2241-2254. https://doi.org/10.2147/NDT.S173280
  38. Petzold A, Steenwijk MD, Eikelenboom JM, Wattjes MP, Uitdehaag BM. Elevated CSF neurofilament proteins predict brain atrophy: a 15-year follow-up study. Mult Scler. 2016;22(9):1154-1162. https://doi.org/10.1177/1352458516645206
  39. Petzold A. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry. 2015;86(12):1388-1390. https://doi.org/10.1136/jnnp-2014-309827
  40. Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J, Baumann NA. Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci. 1978;35:147-155. https://doi.org/10.1016/0022-510X(78)90107-7
  41. Roessmann U, Velasco ME, Sindely SD, Gambetti P. Glial fibrillary acidic protein (GFAP) in ependymal cells during development. An immunocytochemical study. Brain Res. 1980;200:13-21. https://doi.org/10.1016/0006-8993(80)91090-2
  42. Martínez MA, Olsson B, Bau L, Matas E, Cobo Calvo Á, Andreasson U, Blennow K, Romero-Pinel L, Martínez-Yélamos S, Zetterberg H. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550-561. https://doi.org/10.1177/1352458514549397
  43. Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011;258(5):882-888. https://doi.org/10.1007/s00415-010-5863-2
  44. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002;122(1-2):132-139. https://doi.org/10.1007/s10072-012-0974-4
  45. Madeddu R, Farace C, Tolu P, Solinas G, Asara Y, Sotgiu MA, Delogu LG, Prados JC, Sotgiu S, Montella A. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol Sci. 2013;34(2):181-186. https://doi.org/10.1007/s10072-012-0974-4
  46. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127-159. https://doi.org/10.1146/annurev.immunol.23.021704.115628
  47. Okada T, Cyster JG. B cell migration and interactions in the early phase of antibody responses. Curr Opin Immunol. 2006;18:278-285. https://doi.org/10.1016/j.coi.2006.02.005
  48. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler. 2011;17:335-343. https://doi.org/10.1177/1352458510389102
  49. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, Lauda F, Kapfer T, Jesse S, Lehmensiek V, Ludolph AC, Otto M, Tumani H. The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS). PLoS ONE. 2010;5(8):e11986. https://doi.org/10.1371/journal.pone.0011986
  50. Mashayekhi F, Salehi Z, Jamalzadeh HR. Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis. Acta Medica (Hradec Kralove). 2012;55(2):83-86. https://doi.org/10.14712/18059694.2015.60
  51. Khaibullin T, Ivanova V, Martynova E, Cherepnev G, Khabirov F, Granatov E, Rizvanov A, Khaiboullina S. Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients. Front. Immunol. 2017;8:531. https://doi.org/10.3389/fimmu.2017.00531
  52. Losy J, Iwanowski P, Kaufman E, Wójcicka M. CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis. Journal of Medical Science. 2016;85(4):298-300. https://doi.org/10.20883/jms.2016.169
  53. Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, Winokur P, Natrajan M, Wuest SC, Romm E, Panackal AA, Williamson PR, Wu T, Bielekova B. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol. 2015;78(1):3-20. https://doi.org/10.1002/ana.24408
  54. Stilund M, Reuschlein AK, Christensen T, Moller HJ, Rasmussen PV, Petersen T. Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS One. 2014;9(6):e98588. https://doi.org/10.1371/journal.pone.0098588
  55. Öhrfelt A, Axelsson M, Malmeström C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016;22(12):1587-1595. https://doi.org/10.1177/1352458515624558
  56. Hassan-Smith G, Durant L, Tsentemeidou A, Assi LK, Faint JM, Kalra S, Douglas MR, Curnow SJ. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol. 2014;276(1-2):175-1759. https://doi.org/10.1016/j.jneuroim.2014.08.003
  57. Villar LM, Espiño M, Costa-Frossard L, Muriel A, Jiménez J, Alvarez-Cermeño JC. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta. 2012;20;413(23-24):1813-1816. https://doi.org/10.1016/j.cca.2012.07.007
  58. Menéndez-Valladares P, García-Sánchez MI, Adorna Martínez M, et al. Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis. Autoimmun Rev. 2018;pii:1568-9972(18)30259-3. https://doi.org/10.1016/j.autrev.2018.07.010
  59. Christiansen M, Gjelstrup MC, Stilund M, Christensen T, Petersen T, Jon Møller H. Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clin Chem Lab Med. 2018;pii:/j/cclm.ahead-of-print/cclm-2018-0400/cclm-2018-0400.xml https://doi.org/10.1515/cclm-2018-0400
  60. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol. 2002;72:752-761. https://doi.org/10.1189/jlb.72.4.752
  61. Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple Sclerosis Journal. 2010;17(1):32-42. https://doi.org/10.1177/1352458510382247
  62. Szalardy L, Zadori D, Simu M, Bencsik K, Vecsei L, Klivenyi P. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis—osteopontin as a potential marker of clinical severity. Journal of the Neurological Sciences. 2013;331(1-2):38-42. https://doi.org/10.1016/j.jns.2013.04.024
  63. Wen S-R, Liu G-J, Feng R-N, Gong F-C, Zhong H, Duan S-R, Bi S. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology. 2012;244(1-2):94-96. https://doi.org/10.1016/j.jneuroim.2011.12.004
  64. Paul A, Comabella M, Gandhi R. Biomarkers in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine. 2018:a029058. https://doi.org/10.1101/cshperspect.a029058
  65. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Multiple Sclerosis Journal. 2001;7(5):285-289. https://doi.org/10.1177/135245850100700503
  66. Olsson B, Malmeström C, Basun H, Annas P, Höglund K, Lannfelt L, Andreasen N, Zetterberg H, Blennow K. Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials. J Alzheimers Dis. 2012;32(2):273-276. https://doi.org/10.3233/JAD-2012-120931
  67. Malmeström C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. Journal of Neuroimmunology. 2014;269(1-2):87-89. https://doi.org/10.1016/j.jneuroim.2014.02.004
  68. Stoop MP, Singh V, Stingl C, Martin R, Khademi M, Olsson T, Hintzen RQ, Luider TM. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res. 2013;12(3):1101-1107. https://doi.org/10.1021/pr3012107
  69. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010;18;73(6):1117-1132. https://doi.org/10.1016/j.jprot.2010.01.004
  70. Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, Sadiq SA. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler. 2013;19(11):1462-1472. https://doi.org/10.1177/1352458513477923
  71. Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83-89. https://doi.org/10.1002/ana.22247
  72. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017;23(1):62-71. https://doi.org/10.1177/1352458516639384
  73. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707-714. https://doi.org/10.1001/archneurol.2010.99
  74. Cross AH, Klein RS, Piccio L. Rituximab combination therapy in relapsing multiple sclerosis. Ther Adv Neurol Disord. 2012;5(6):311-319. https://doi.org/10.1177/1756285612461165
  75. Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20(1):43-50. https://doi.org/10.1177/1352458513490544
  76. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Markers for different glial cell responses in multiple sclerosis: Clinical and pathological correlations. Brain. 2002;125:1462-1473. https://doi.org/10.1093/brain/awf165
  77. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Nat Med. 2006;12:138-143. https://doi.org/10.1126/scitranslmed.aaa8038
  78. Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L. BHT-3009 Study Group. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008;63:611-620. https://doi.org/10.1002/ana.21370
  79. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, Lucas M, Basso AS, Khoury SJ, Lucchinetti CF, Cohen IR, Weiner HL. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(48):18889-18894. https://doi.org/10.1073/pnas.0806310105
  80. Hecker M, Fitzner B, Wendt M, Lorenz P, Flechtner K, Steinbeck F, Schröder I, Thiesen HJ, Zettl UK. High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Molecular & cellular proteomics: MCP. 2016;15(4):1360-1380. https://doi.org/10.1074/mcp.M115.051664
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.